CHINA RES POWER (00836): "22 CR Y4" will be repaid and delisted on December 12th.

17:33 10/12/2025

China Resources Power (00836) announced that China Resources Power Investment Limited (hereinafter referred to as the "issuer" or "company") will pay interest and principal of the corporate bonds open to professional investors for subscription in 2022 (third tranche) (variety two) from December 12, 2024 to December 11, 2025 (hereinafter referred to as "current year") on December 12, 2025. The bonds are referred to as "22 China Resources Y4", with a code of 148144.SZ, a face value interest rate of 3.93%, and a total issuance amount of 1.8 billion yuan.

CHINA RES POWER (00836) announced that CHINA RES POWER INVESTMENT CO., LTD. (hereinafter referred to as the "issuer" or "company") will publicly issue renewable corporate bonds (third series) targeting professional investors in 2022, which will be due on December 12, 2025. The interest and principal of the bonds for the period from December 12, 2024 to December 11, 2025 (referred to as the "current year") will be paid on December 12, 2025. The bonds are abbreviated as "22 CRC Y4", bond code 148144.SZ, with a coupon rate of 3.93% and a total issuance amount of 1.8 billion yuan.

Western Metal Materials (002149.SZ) shareholders Xi'an Aerospace have cumulatively reduced their stake by 1.46%.

CSPC PHARMA (01093): Recombinant fully human anti-ACTRIIA / IIB monoclonal antibody (JMT206) approved for clinical trials in the United States.

Shanghai Fosun Pharmaceutical (02196): The drug registration application for sodium phosphonoformate injection has been approved by the National Medical Products Administration.

Western Metal Materials (002149.SZ) shareholders Xi'an Aerospace have cumulatively reduced their stake by 1.46%.

CSPC PHARMA (01093): Recombinant fully human anti-ACTRIIA / IIB monoclonal antibody (JMT206) approved for clinical trials in the United States.

Shanghai Fosun Pharmaceutical (02196): The drug registration application for sodium phosphonoformate injection has been approved by the National Medical Products Administration.